162363-46-4 Usage
General Description
4-CHLORO-6,7-DIETHOXY-QUINAZOLINE is a chemical compound with the molecular formula C12H14ClN3O2. It is a quinazoline derivative that contains a chlorine atom and two ethoxy groups. 4-CHLORO-6,7-DIETHOXY-QUINAZOLINE has shown potential pharmacological activity and has been studied for its potential use in the development of pharmaceutical drugs. Its properties make it a valuable building block for the synthesis of various bioactive compounds. Further research is needed to fully understand and utilize the potential applications of 4-CHLORO-6,7-DIETHOXY-QUINAZOLINE in the field of medicinal chemistry.
Check Digit Verification of cas no
The CAS Registry Mumber 162363-46-4 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,6,2,3,6 and 3 respectively; the second part has 2 digits, 4 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 162363-46:
(8*1)+(7*6)+(6*2)+(5*3)+(4*6)+(3*3)+(2*4)+(1*6)=124
124 % 10 = 4
So 162363-46-4 is a valid CAS Registry Number.
162363-46-4Relevant articles and documents
NOVEL 4-(TETRAZOL-5-YL)-QUINAZOLINE DERIVATIVES AS ANTI CANCER AGENT
-
Page/Page column 19, (2010/11/03)
The invention relates to substituted 4-(tetrazol-5-yl)-quinazoline derivatives of the formula-I, or pharmaceutically-acceptable salts thereof, which possess anti-proliferative activity such as anti-cancer activity and are accordingly useful in methods of
NOVEL 4-(TETRAZOL-5-YL)-QUINAZOLINE DERIVATIVES AS ANTI CANCER AGENTS
-
Example 5, (2009/06/27)
The invention relates to substituted 4-(tetrazol-5-yl)-quinazoline derivatives of the formula-I, or pharmaceutically-acceptable salts thereof, which possess anti-proliferative activity such as anti-cancer activity and are accordingly useful in methods of
Fructose 1,6-bisphosphatase inhibitors
-
, (2008/06/13)
The present invention relates to certain quinazoline compounds which have utility in the treatment of diabetes mellitus, hypercholesterolemia, hyperlipidemia, diabetic complications and cancer. The invention also relates to pharmaceutical compositions and